Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Retrovirology Année : 2016

Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers

Résumé

AbstractBackgroundHuman endogenous retroviruses (HERVs) comprise approximately 8% of the human genome and while the majority are transcriptionally silent, the most recently integrated HERV, HERV-K (HML-2), remains active. During HIV infection, HERV-K (HML-2) specific mRNA transcripts and viral proteins can be detected. In this study, we aimed to understand the antibody response against HERV-K (HML-2) Gag in the context of HIV-1 infection.ResultsWe developed an ELISA assay using either recombinant protein or 164 redundant “15mer” HERV-K (HML-2) Gag peptides to test sera for antibody reactivity. We identified a total of eight potential HERV-K (HML-2) Gag immunogenic domains: two on the matrix (peptides 16 and 31), one on p15 (peptide 85), three on the capsid (peptides 81, 97 and 117), one on the nucleocapsid (peptide 137) and one on the QP1 protein (peptide 157). Four epitopes (peptides 16, 31, 85 and 137) were highly immunogenic. No significant differences in antibody responses were found between HIV infected participants (n = 40) and uninfected donors (n = 40) for 6 out of the 8 epitopes tested. The antibody response against nucleocapsid (peptide 137) was significantly lower (p < 0.001), and the response to QP1 (peptide 157) significantly higher (p < 0.05) in HIV-infected adults compared to uninfected individuals. Among those with HIV infection, the level of response against p15 protein (peptide 85) was significantly lower in untreated individuals controlling HIV (“elite” controllers) compared to untreated non-controllers (p < 0.05) and uninfected donors (p < 0.05). In contrast, the response against the capsid protein (epitopes 81 and 117) was significantly higher in controllers compared to uninfected donors (p < 0.001 and <0.05 respectively) and non-controllers (p < 0.01 and <0.05). Peripheral blood mononuclear cells (PBMCs) from study participants were tested for responses against HERV-K (HML-2) capsid recombinant peptide in gamma interferon (IFN-γ) enzyme immunospot (Elispot) assays. We found that the HERV-K (HML-2) Gag antibody and T cell response by Elispot were significantly correlated.ConclusionsHIV elite controllers had a strong cellular and antibody response against HERV-K (HML-2) Gag directed mainly against the Capsid region. Collectively, these data suggest that anti-HERV-K (HML-2) antibodies targeting capsid could have an immunoprotective effect in HIV infection.
Fichier principal
Vignette du fichier
12977_2017_Article_365.pdf (1022.72 Ko) Télécharger le fichier
12977_2017_365_MOESM2_ESM.pdf (13.16 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Origine : Publication financée par une institution

Dates et versions

inserm-01577633 , version 1 (27-08-2017)

Identifiants

Citer

Miguel de Mulder, Devi Sengupta, Steven G. Deeks, Jeffrey N. Martin, Christopher D. Pilcher, et al.. Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers. Retrovirology, 2016, 14 (1), pp.41. ⟨10.1186/s12977-017-0365-2⟩. ⟨inserm-01577633⟩
141 Consultations
237 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More